Pain Therapeutics Files Form 8-K Regarding Correspondence From Pfizer, Inc.
AUSTIN, Texas, May 10, 2013 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc.
(Nasdaq:PTIE) announced today that yesterday it received correspondence from
Pfizer, Inc. (NYSE:PFE).
This correspondence is available at: http://investor.paintrials.com/sec.cfm.
The company furnished the correspondence with the Securities and Exchange
Commission pursuant to the submission of a Current Report on Form 8-K.
About Pain Therapeutics, Inc.
Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel
drugs.The FDA has not approved any of our drug candidates for commercial
sale. For more information, please visit www.paintrials.com.
CONTACT: For More Information Contact:
Peter S. Roddy
Vice President and Chief Financial Officer
Pain Therapeutics, Inc.
Press spacebar to pause and continue. Press esc to stop.